| 1 |
Kawasaki T, Kosaki F, Okawa S, Shig ernatsu I, Yanagawa H A new infantile acute febrile mucocutaneous lymph node syndrome (11LNS) prevailing in Japan, Pediatrics 197454: 271-6.
|
| 2 |
FitzGerald GA. Dipyridamole. N Engl J Med 1987:316:1247-1257.
DOI
ScienceOn
|
| 3 |
Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999:100:1667-72.
DOI
ScienceOn
|
| 4 |
Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE et al. The treatment of Kawasaki syndrome with intravenous gamma globulin, N Engl J Med 1986;315: 341-7.
DOI
ScienceOn
|
| 5 |
Terai M, Shulman ST. Prevalence of coronary artery abnor¬malities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose, J Pediatr 1997:131:888-93
DOI
ScienceOn
|
| 6 |
Durongpisitkul K, Soong swang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C, Irnrnunoglobulin failure and retreatment in Kawasaki disease, Pediatr Cardiol 2003; 24:145-8.
DOI
|
| 7 |
Newburger IW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL et al. Pediatric Heart Network Inve¬stigators, Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease, N Engl J Med 2007;356:663-75.
DOI
ScienceOn
|
| 8 |
Wallace CA, French IW, Kahn SJ, Sherry DD, Initial intravenous gamma-globulin treatment failure in Kawasaki disease, Pediatrics 2000;105:E78,
DOI
ScienceOn
|
| 9 |
Lahdenne P, Vhsalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopa¬thic arthritis: an open label study, Ann Rheum Dis 2003; 62:245-7.
DOI
ScienceOn
|
| 10 |
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha -neutralizing agent, N Engl J Med 2002;346:623-6.
DOI
ScienceOn
|
| 11 |
Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel IN, Wise RP, Brown SL, Udall JN Jr. Braun Mlvl. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70,
DOI
ScienceOn
|
| 12 |
Armbrust W, Karnphuis SS, Wolfs TW, Fiselier TJ, Nikkels PG, Kuis W et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology 2004;43:527-9.
DOI
ScienceOn
|
| 13 |
Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD et al. Pediatric Rheumatology Collaborative Study Group, Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheurnatoid arthritis, Arthritis Rheum 200654:1987-94
DOI
ScienceOn
|
| 14 |
Burns JC, Capparelli EV, Brown JA, Newburger JW, Glade 11P, Intravenous gamma-globulin treatment and retreatment in Kawasaki disease, US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998:17:1144-8.
DOI
ScienceOn
|
| 15 |
Sunde1 RP, Baker AL, Fulton DR, Newburger JW, Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial, J Pediatr 2003;142:611-6,
DOI
ScienceOn
|
| 16 |
Foster RH, Wiseman LR Abciximab. An updated review of its use in ischaemic heart disease, Drugs 1998;56:629-65
DOI
|
| 17 |
Behan MW, Storey RF. Antip1ate1et therapy in cardiovascular disease, Postgrad Med J 2004;80: 155-164,
DOI
|
| 18 |
Behan MW, Storey RF. Antip1ate1et therapy in cardiovascular disease, Postgrad Med J 2004;80:155-164,
DOI
|
| 19 |
Burns JC, Mason WH, Hauger SB, janai H, Bastian IF, Wohrley JD et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7.
DOI
ScienceOn
|
| 20 |
Matsubara T, Furukawa S, Yabuta K Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary artery lesions, Clin Immunol Immunopathol 1990;56:29-36,
DOI
ScienceOn
|
| 21 |
Etheridge SP, Tani L Y, Minich LL, Revenaugh JR Platelet glycoprotein Ilb/Illa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease, Cathet Cardiovasc Diagn 1998;45:264-8,
DOI
ScienceOn
|
| 22 |
Riegert-johnson DL, Godfrey JA, Myers JL, Hubrnayr RD, Sandborn WJ, Loftus EV Jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion, Inflamm Bowel Dis 2002:8:186-91.
DOI
ScienceOn
|
| 23 |
Newburger JW, Treatment of Kawasaki disease: cortico-steroids revisited, J Pediatr 1999;135:411-3,
DOI
ScienceOn
|
| 24 |
Furusho K, Sato K, Soeda T, Matsumoto H, Okabe T, Hirota T et al. High-dose intravenous garnrnaglobulin for Kawasaki disease, Lancet 1983;2:1359,
|
| 25 |
Marasini M, Pongig lione G, Gazzolo D, Campelli A, Ribal¬done D, Caponnetto S, Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities, Am J Cardiol 1991 68: 796-7.
DOI
ScienceOn
|
| 26 |
Lee MS, An SY, jang GC, Kim DS, A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate, Yonsei Med J 2002;43:527-32,
DOI
|
| 27 |
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991:324:1633-9.
DOI
ScienceOn
|
| 28 |
Inarno Y, Okubo T, Wada M, Fuchig arni S, Hashimoto K, Fuchigarni T, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients, Three case reports, Int Arch Allergy Irnrmmol 2002;127:89-94.
DOI
ScienceOn
|
| 29 |
Crandall WV, Mackner LM, Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84,
|
| 30 |
Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement, Pediatrics 1979; 63:175-9.
|
| 31 |
Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichirnaru T, Fujita I et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase¬type 2 in Kawasaki disease, J Infect Dis 2000;181:1101-9,
DOI
ScienceOn
|
| 32 |
De Rycke L, Kruithof E, Van Darnrne N, Hoffman IE, Van den Bossche N, Van den Bosch F et al. Antinuclear antibodies following infliximab treatment in patients with rheurnatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015-23.
DOI
ScienceOn
|
| 33 |
Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS, Infliximab (RE¬11ICADE) therapy in the treatment of pediatric Crohn' s disease, Am J Gastroenterol 2003;98:833-8,
DOI
|
| 34 |
Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease, Eur J Pediatr 1994;153:663-7.
DOI
|
| 35 |
Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A et al. Influence of irnrmmogenicity on the long-term efficacy of infliximab in Crohn'.s disease, N Engl J Med 2003;348:601-8.
DOI
ScienceOn
|
| 36 |
Patrono C, Coller B, Dalen JE, Fuster V, Gent M, Harker LA et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects, Chest 1998;114(5 Suppl):470S-88S.
DOI
ScienceOn
|
| 37 |
Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS, Infliximab (RE11ICADE) therapy in the treatment of pediatric Crohn'.s disease.Am J Gastroenterol 2003;98:833-8,
DOI
|
| 38 |
Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-S, interieukin-S, and tumor necrosis factor alpha among patients with Kawasaki disease, J Pediatr 1992; 121:924-6.
DOI
|
| 39 |
Lahdenne P, Vhsalo P, Honkanen V, Infliximab or etanercept in the treatment of children with refractory juvenile idiopa¬thic arthritis: an open label study, Ann Rheum Dis 2003;62: 245-7.
DOI
ScienceOn
|
| 40 |
Melish ME. Kawasaki syndrome, Pediatr Rev 1996;17:153-62,
DOI
|
| 41 |
Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburg er IW, Pober JS, Endothelial activation in the pathogenesis of Kawasaki disease, Trans Assoc Am Physicians 1989;102: 131-8.
|
| 42 |
Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose, J Pediatr 1997;131:888-93.
DOI
ScienceOn
|
| 43 |
Wright DA, Newburger JW, Baker A, Sunde1 RP, Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids, J Pediatr 1996;128:146-9,
DOI
ScienceOn
|
| 44 |
Weiss JE, Eberhard BA, Chowdhury D, Gottheb BS. Infliximab as a novel therapy for refractory Kawasaki disease, J Rheumatol 2004;31:808-10.
|
| 45 |
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun Mlvl. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration, Arthritis Rheum 2002;46: 3151-8.
DOI
ScienceOn
|
| 46 |
Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease, Postgrad Med J 2004;80: 155-64,
DOI
|
| 47 |
O'Brien M, Parness lA, Neufeld EJ, Baker AL, Sunde1 RP, Newburger JW, Ticlopidine plus aspirin for coronary throm¬bosis in Kawasaki disease, Pediatrics 2000;105:E64,
DOI
ScienceOn
|
| 48 |
Han RK, Silverman ED, Newman A, McCrindle BW, Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Ka¬wasaki disease. Arch Pediatr Adolesc Med 2000;154:694-9.
DOI
|
| 49 |
Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW, Gamma globulin retreatrnent in Kawasaki disease, J Pediatr 1993:123:657-9.
DOI
ScienceOn
|
| 50 |
Wallace CA, French JW, Kahn SJ, Sherry DD, Initial intravenous garnrnaglobulin treatment failure in Kawasaki disease, Pediatrics 2000;105:E78,
DOI
ScienceOn
|
| 51 |
Raman V, Kim J, Sharkey A, Chatila T. Response of refrac¬tory Kawasaki disease, Pediatr Infect Dis J 2001 20:635-37,
DOI
ScienceOn
|
| 52 |
Cohen RD, Tsang IF, Hanauer SB. Infliximab in Crohn'.s disease: first anniversary clinical experience, Am J Gastroenterol 2000;95:3469-77.
DOI
|
| 53 |
Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed 11D, Ferrieri P et al. Guidelines for long term management of patients with Kawasaki disease, Report from the Com¬mittee on Rheumatic Fever, Endocarditis, and Kawasaki disease, Council on Cardiovascular Disease in the Young, Americal Heart Association, Circulation 1994;89:916-22,
DOI
ScienceOn
|
| 54 |
Kroesen S, Widmer AF, Tyndall A, Hasler P, Serious bacterial infections in patients with rheurnatoid arthritis under anti-TNF-alpha therapy, Rheumatology 2003;42:617-21.
DOI
ScienceOn
|
| 55 |
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Committee on Rheumatic Fever Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, Pediatrics 2004;114:1708-33,
DOI
ScienceOn
|
webmaster
